ClinicalTrials.gg
Active, not recruitingNCT06140836Updated Sep 22, 2026

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

A Phase 3 interventional study of Repotrectinib and Crizotinib in Carcinoma, Non-Small-Cell Lung, sponsored by Bristol-Myers Squibb. Active, not recruiting at 122 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
190
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb — 21 open to participants now, 35 under way, 10 of them phase 3. Carcinoma, Non-Small-Cell Lung · Bristol-Myers Squibb.

Planned enrollment
50th of 107
190 · median 169
Started
2023
with 5 others
Phase 3
27 of 131
5 open now
Primary completion
2027-02
later than 9 of 34 live
Registered
103rd of 131
by date

Among the 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb, this one is the 50th largest by planned enrollment of the 107 interventional ones that give a count, is one of 6 that started in 2023, is one of 27 in phase 3, reaches primary completion later than 9 of the 34 other live ones, and was the 103rd registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

21 of the 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of repotrectinib and crizotinib in participants with locally advanced or metastatic TKI-naïve ROS1-positive non-small cell lung cancer (NSCLC).

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung

Keywords

  • TKI-naïve
  • ROS1
  • NSCLC
  • ROS1-positive non-small cell lung cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has or cytologically confirmed diagnosis of locally advanced or NSCLC
  • Participant has a ROS1 gene rearrangement/fusion as detected by a local test.
  • At least 1 according to v1.1, as assessed by the investigator.
  • Participants must not be exposed previously with TKIs that demonstrated activities in ROS1-positive NSCLC
  • Up to 1 for NSCLC is permitted
  • Performance Status ≤ 2

Exclusion criteria

Exclusion Criteria:

  • Symptomatic or symptomatic .
  • History of previous cancer requiring therapy within the previous 2 years, except for NSCLC under study, squamous cell or basal-cell carcinoma of the skin, or any in situ carcinoma that has been completely resected.
  • Known tumor targetable co-mutations or rearrangements
  • cardiovascular disease (either active or within 6 months prior to enrollment)

Note: Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
190 participants (estimated)

Study arms

  • Experimental
    Arm A

    Drug: Repotrectinib

  • Active comparator
    Arm B

    Drug: Crizotinib

Interventions

  • Specified dose on specified days

    Also known as: BMS-986472

  • Specified dose on specified days

    Also known as: Xalkori

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) as per Blinded Independent Central Review (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    Time frame: Up to approximately 41 months

Secondary outcomes

  1. Overall Survival (OS)

    Time frame: Up to approximately 41 months

  2. Overall Response Rate (ORR) as per BICR according to RECIST v1.1

    Time frame: Up to approximately 41 months

  3. ORR as per Investigator according to RECIST v1.1

    Time frame: Up to approximately 41 months

  4. Duration of Response (DOR) as per BICR according to RECIST v1.1

    Time frame: Up to approximately 41 months

  5. DOR as per Investigator according to RECIST v1.1

    Time frame: Up to approximately 41 months

  6. Time to Response (TTR) as per BICR according to RECIST v1.1

    Time frame: Up to approximately 41 months

  7. TTR as per Investigator according to RECIST v1.1

    Time frame: Up to approximately 41 months

  8. PFS as per Investigator according to RECIST v1.1

    Time frame: Up to approximately 41 months

  9. Time to intracranial progressions as per BICR according to RECIST v1.1

    Time frame: Up to approximately 41 months

  10. Number of participants with Adverse Events (AEs), Serious AEs (SAEs), AEs leading to study intervention discontinuation, and drug-related AEs

    Time frame: Up to 30 days after last dose

  11. Number of deaths

    Time frame: Up to 30 days after last dose

  12. Number of participants without at least a 3-point change in the Non-Small Cell Lung Cancer-Symptom Assessment Questionnaire (NSCLC-SAQ) total score

    Time frame: Up to 30 days after last dose

07

Study locations

122 sites
  • Local Institution - 0221
    Des Moines, Iowa 50309, United States
  • Local Institution - 0075
    Boston, Massachusetts 02114, United States
  • Local Institution - 0201
    Boston, Massachusetts 02215, United States
  • Local Institution - 0210
    Mineola, New York 11501, United States
  • Local Institution - 0134
    New York, New York 10016, United States
  • Local Institution - 0214
    Tacoma, Washington 98405, United States
  • Local Institution - 0092
    Ciudad Autónoma de Buenos Aires, Buenos Aires 1280, Argentina
  • Instituto Alexander Fleming
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1426ANZ, Argentina
  • Local Institution - 0091
    ABB, Buenos Aires F.D. C1199ABB, Argentina
  • Local Institution - 0106
    Buenos Aires, 1431, Argentina
  • Local Institution - 0207
    Buenos Aires, C1417DTB, Argentina
  • Local Institution - 0093
    Córdoba, 5000, Argentina
  • Local Institution - 0041
    Vienna, 1210, Austria
  • Local Institution - 0073
    Belo Horizonte, Minas Gerais 30380-490, Brazil
  • Local Institution - 0033
    Porto Alegre, Rio Grande do Sul 90110-270, Brazil
  • Local Institution - 0034
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • Local Institution - 0029
    Barretos, São Paulo 14784400, Brazil
  • Local Institution - 0037
    São José do Rio Preto, São Paulo 15090000, Brazil
  • Local Institution - 0209
    São Paulo, São Paulo 01308-060, Brazil
  • Local Institution - 0147
    São Paulo, São Paulo 01321-001, Brazil
  • Local Institution - 0098
    Rio de Janeiro, 22061-080, Brazil
  • Local Institution - 0108
    Rio de Janeiro, 22250-905, Brazil
  • Local Institution - 0032
    São Paulo, 01401-002, Brazil
  • Local Institution - 0114
    São Paulo, 05652-900, Brazil
  • Local Institution - 0002
    Toronto, Ontario M5G 2M9, Canada
  • Local Institution - 0123
    Trois-Rivières, Quebec G8Z 3R9, Canada
  • Fundacion Arturo Lopez Perez (FALP)
    Santiago, Santiago Metropolitan 7500921, Chile
  • Local Institution - 0096
    Viña del Mar, Valparaiso 2520598, Chile
  • Local Institution - 0168
    Beijing, Beijing Municipality 100142, China
  • Local Institution - 0185
    Chongqing, Chongqing Municipality 400042, China
  • Local Institution - 0169
    Xiamen, Fujian 361003, China
  • Local Institution - 0180
    Guangzhou, Guangdong 510120, China
  • Local Institution - 0194
    Nanning, Guangxi 530000, China
  • Local Institution - 0171
    Harbin, Heilongjiang 150000, China
  • Local Institution - 0166
    Zhengzhou, Henan 450003, China
  • Local Institution - 0181
    Wuhan, Hubei 430079, China
  • Local Institution - 0184
    Changsha, Hunan 410000, China
  • Local Institution - 0193
    Nanjing, Jiangsu 210029, China
  • Local Institution - 0202
    Nanchang, Jiangxi 330006, China
  • Local Institution - 0178
    Changchun, Jilin 130012, China
  • Local Institution - 0183
    Xi'an, Shaanxi 710061, China
  • Local Institution - 0186
    Jinan, Shandong 250000, China
  • Local Institution - 0164
    Shanghai, Shanghai Municipality 200030, China
  • Local Institution - 0179
    Shanghai, Shanghai Municipality 200032, China
  • Local Institution - 0177
    Chengdu, Sichuan 610044, China
  • Local Institution - 0175
    Hangzhou, Zhejiang 310022, China
  • Local Institution - 0059
    Strasbourg, Alsace 67091, France
  • Local Institution - 0055
    Pessac, Aquitaine 33600, France
  • Local Institution - 0109
    Dijon, Côte-d'Or 21079, France
  • Local Institution - 0057
    Rouen, Haute-Normandie 76031, France
  • Local Institution - 0058
    La Tronche, Isère 38700, France
  • Local Institution - 0189
    Saint-Herblain, Loire-Atlantique 44800, France
  • Local Institution - 0060
    Pierre-Bénite, Rhône 69310, France
  • Local Institution - 0056
    Paris, 75014, France
  • Klinikum Esslingen
    Esslingen am Neckar, Baden-Wurttemberg 73730, Germany
  • Klinikum Würzburg Mitte
    Würzburg, Bavaria 97074, Germany
  • Local Institution - 0074
    Oldenburg, Lower Saxony 26121, Germany
  • Evangelische Lungenklinik Berlin
    Berlin, 13125, Germany
  • Universitaetsklinikum Koeln
    Cologne, 50937, Germany
  • Local Institution - 0035
    Dresden, 01307, Germany
  • Asklepios Klinik Gauting GmbH
    Gauting, 82131, Germany
  • Lungenfachklinik Immenhausen
    Immenhausen, 34376, Germany
  • Marienhaus Klinikum Mainz
    Mainz, 55131, Germany
  • Local Institution - 0154
    Pátrai, Achaḯa 26504, Greece
  • Local Institution - 0153
    Athens, Attikí 115 27, Greece
  • Local Institution - 0155
    Chaïdári, Attikí 124 62, Greece
  • "Theagenio" Cancer Hospital of Thessaloniki
    Thessaloniki, Kentrikí Makedonía 540 07, Greece
  • Local Institution - 0135
    Budapest, 1121, Hungary
  • Local Institution - 0102
    Ahmedabad, Gujarat 380054, India
  • Local Institution - 0118
    Ahmedabad, Gujarat 380060, India
  • Local Institution - 0044
    Gurugram, Haryana 122001, India
  • Local Institution - 0082
    Bengaluru, Karnataka 560017, India
  • Local Institution - 0045
    Pune, Maharashtra 411001, India
  • Local Institution - 0049
    Pune, Maharashtra 411004, India
  • Local Institution - 0218
    New Delhi, National Capital Territory of Delhi 110029, India
  • Local Institution - 0076
    New Delhi, National Capital Territory of Delhi 110085, India
  • Local Institution - 0151
    Aviano, Friuli Venezia Giulia 33081, Italy
  • Local Institution - 0152
    Milan, Lombardy 20133, Italy
  • Local Institution - 0149
    Monza, Lombardy 20900, Italy
  • Local Institution - 0150
    Naples, Napoli 80131, Italy
  • Local Institution - 0148
    Rome, Roma 00144, Italy
  • Local Institution - 0190
    Nagoya, Aichi-ken 466-8560, Japan
  • Local Institution - 0132
    Kashiwa, Chiba 277-8577, Japan
  • Local Institution - 0174
    Matsuyama, Ehime 791-0280, Japan
  • Local Institution - 0163
    Sapporo, Hokkaido 060-8648, Japan
  • Local Institution - 0173
    Yokohama, Kanagawa 2418515, Japan
  • Sendai Kosei Hospital
    Sendai, Miyagi 9800873, Japan
  • Tokyo Metropolitan Komagome Hospital
    Bunkyo Ku, Tokyo 113-8677, Japan
  • Local Institution - 0159
    Yonago, Tottori 683-8504, Japan
  • Local Institution - 0195
    Fukuoka, 811-1395, Japan
  • Local Institution - 0160
    Osaka, 534-0021, Japan
  • Local Institution - 0167
    Osaka, 541-8567, Japan
  • Tokyo Metropolitan Police Hospital
    Tokyo, 164-8541, Japan
  • Local Institution - 0216
    Amsterdam, North Holland 1081 HV, Netherlands
  • Local Institution - 0187
    Lublin, Lublin Voivodeship 20-609, Poland
  • Local Institution - 0196
    Olsztyn, Warmian-Masurian Voivodeship 10-357, Poland
  • Local Institution - 0030
    Bucharest, Bucharest 013812, Romania
  • Local Institution - 0066
    Bucharest, Bucharest 022328, Romania
  • Local Institution - 0031
    Craiova, Dolj 200746, Romania
  • Local Institution - 0122
    Cluj-Napoca, 400015, Romania

Showing the first 100 of 122 sites across 21 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Feb 2027, 37 months after the start.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 37 months is close to that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2023
First posted
Nov 20, 2023
StartActual
Dec 21, 2023
Primary completionEst.
Feb 16, 2027
CompletionEst.
Mar 15, 2027
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06140836
Responsible party
Sponsor
First posted
Nov 20, 2023
Start date
Dec 21, 2023
Primary completion
Feb 16, 2027 (estimated)
Completion
Mar 15, 2027 (estimated)
Last update
Sep 22, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Repotrectinib

Start the discussion